|
|
Other links at Articles > Diabetes and Endocrinology |
| 2. |
Safety Study Finds Glargine Not Associated With Retinopathy
|
|
|
The safety of the insulin analog glargine (Lantus, Sanofi-Aventis, Paris) was demonstrated in a 5-year post-marketing evaluation of the drug, in which there was no evidence of an increased risk of retinopathy with long-term glargine use. Reuters Health Information
|
|
|